Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to test the hypothesis that using Sipuleucel-T (Provenge) in
combination with new hormonal agents (NHA) (abiraterone, enzalutamide, apalutamide) for the
treatment of participants with asymptomatic metastatic castration resistant prostate cancer
(mCRPC) and no visceral metastases would enhance the activation of antigen presenting cells
(APC) by sipuleucel-T.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute